313 results
8-K
EX-99.1
INCY
Incyte Corp.
30 Apr 24
Incyte Reports 2024 First Quarter Financial Results and Provides Updates
7:10am
cost of product revenues
Non-GAAP cost of product revenues1
GAAP research and development
Non-GAAP research and development2
GAAP selling, general … of the European business of ARIAD Pharmaceuticals, Inc. and the cost of stock-based compensation.
2 Non-GAAP research and development expenses exclude
S-8
EX-99.1
INCY
Incyte Corp.
13 Feb 24
Registration of securities for employees
5:06pm
, including but not limited to regulatory achievements, (s) achievement of research and development objectives, or (t) formation of joint ventures … , strategic relationships or other commercial, research or development collaborations (“Qualifying Performance Criteria”). The Committee may appropriately
8-K
EX-99.1
bpahe1jt8 xy0s7s3br8
13 Feb 24
Provides 2024 Financial Guidance and Highlights R&D Priorities
7:03am
8-K
EX-99.1
p0mfyoci3 yuhxqnpm
31 Oct 23
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates
7:05am
8-K
EX-99.1
8f57fjn
1 Aug 23
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates
7:05am
8-K
EX-10.1
i4q3xx
15 Jun 23
Departure of Directors or Certain Officers
2:10pm
8-K
rtp 6dn1adyh
8 May 23
Other Events
5:21pm
8-K
EX-99.1
70m1 k9seramey7dq
2 May 23
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
7:01am
8-K
EX-99.1
3jkwtrpbh
1 Nov 22
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key
7:05am